CPRX Catalyst Pharmaceuticals, Inc.

3.600.11 (+3.15%)
IEX real time price: 10:15:47 AM

Quote

Previous Close
$3.49
Day Range
$3.50-$3.63
52 Week Range
$1.85-$6.16
Volume
227,226
Avg Volume
3,507,420
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$370.27M
Enterprise Value (EV)
$311.65M
PE Ratio
-
EV/EBITDA
-8.84
Price/Sales
-
Price/Book
7.07
PEG Ratio
0.15

Financials

Revenue
-
Gross Profit
-
EBITDA
-$35.26M
EPS, ttm
-$0.28
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
8/5/2019 (73 days)
Debt to Equity
-
Debt
-
Cash
$53.48M
Net Debt
-

Performance

Beta
1.45
200 Day Moving Avg
$3.31
50 Day Moving Avg
$4.65
52 Week Change
2.65%
YTD Change
68.55%
1 Month Change
-35.25%
3 Month Change
21.18%
6 Month Change
19.11%
1 Year Change
2.65%
2 Year Change
253.18%
5 Year Change
226.74%

Share Count

Shares Outstanding
102.9M
Float
95.6M
Restricted Shares
7.3M
Restricted Shares, %
7.07%

Catalyst Pharmaceuticals, Inc. Company Details

Sector: Health Technology

Industry: Pharmaceuticals: Other

CEO: Patrick J. McEnany

Website: http://www.catalystpharma.com

Description: Catalyst Pharmaceuticals is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasmsThe company was founded Huckel E. Hubert in January 2002 and is headquartered in Coral Gables, FL.

Employees: 51